• Corpus ID: 12588288

Expression of cyclooxygenase-1 and -2 in human colorectal cancer.

  title={Expression of cyclooxygenase-1 and -2 in human colorectal cancer.},
  author={Hajime Sano and Yutaka Kawahito and Ronald L. Wilder and Akira Hashiramoto and Shigehiko Mukai and Kiyoshi Asai and Shigeru Kimura and Haruki Kato and Motoharu Kondo and Timothy Hla},
  journal={Cancer research},
  volume={55 17},
Several studies indicate that nonsteroidal anti-inflammatory drugs including indomethacin, aspirin, sulindac, and piroxicam reduce the risk of colon cancer. Furthermore, nonsteroidal anti-inflammatory drugs that inhibit the cyclooxygenase (COX) enzyme were shown to inhibit the development of colon cancer in animal models of carcinogenesis. Non-steroidal anti-inflammatory drugs inhibit the enzymatic activity of both the constitutive (COX-1) and inducible (COX-2) isoforms of COX enzyme. We have… 

Expression of cyclooxygenase-2 in human lung carcinoma.

The data suggest that Cox-2 is expressed in human lung carcinomas and in precursor lesions leading to this malignancy.

Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer.

The results suggest that overexpression of COX may not be unique to colon cancer and may be a feature common to other epithelial tumors.

Cyclooxygenases and colon cancer.

Advances in Brief Expression of Cyclooxygenase-2 in Human Lung Carcinoma 1

Interestingly, atypical alveolar epithelium, which associates with asbestosis and idiopathic fibrosing alveolitis and is considered to be a precursor lesion for lung cancer, expressed the Cox-2 protein.

Role of cyclooxygenase-2 in colorectal cancer

Data indicate that COX-2 is involved in the regulation of apoptosis, angiogenesis, and tumor cell invasiveness, which appear to contribute to its effects on tumorigenesis.

Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential.

It is demonstrated that constitutive expression of COX-2 can lead to phenotypic changes that alter the metastatic potential of colorectal cancer cells and be reversed by treatment with sulindac sulfide, a known COX inhibitor.

Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2.

Evidence is provided that there may be a direct link between inhibition of intestinal cancer growth and selective inhibition of the COX-2 pathway.

The selective cyclooxygenase-1 inhibitor SC-560 suppresses cell proliferation and induces apoptosis in human hepatocellular carcinoma cells.

It is reported for the first time that the selective COX-1 inhibitor SC-560 exhibits anti-tumor and apoptotic effects in human HCC cells.

Cyclooxygenase-2 inhibitors in colorectal cancer.